Ray Therapeutics
PublicRay Therapeutics is now publicly traded
The data on this page reflects Ray Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Apr 21, 2026
Total Funding Raised
$372M
Company Overview
Ray Therapeutics is a biotechnology company that develops innovative optogenetic gene therapies aimed at treating patients with blinding diseases.
Sector
SaaS
Verticals
HealthTech, Life Sciences
AI Layer
Non-AI
Keywords
Ray Therapeutics Comparables
Compare Ray Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gensight Biologics | 82% | |
| Bionic Sight, Inc. | 82% | |
| Beacon Therapeutics | 81% |
Ray Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 21, 2026 | ||||
| Grant | Apr 24, 2025 | ||||
| Series B | Apr 23, 2024 | ||||
| Grant | Nov 13, 2023 | ||||
| Series A | May 16, 2023 | ||||
Grant | Apr 26, 2022 |
Ray Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series B |
| Janus Henderson Group | Series B |
| Franklin Advisers | Series B |
| 4BIO Capital | Series A, Series B, Seed |
| Norwest Venture Partners | Series A, Series B |
| Novo Holdings | Series B |
| Adage Capital Management | Series B |
Ray Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access